DOJ Formally Proposes Easing Cannabis Restrictions, Paving Way for Major Tax Relief

WASHINGTON — The Department of Justice formally moved on May 16, 2024, to reclassify marijuana as a less dangerous substance, a landmark decision that could dismantle a decades-old tax rule that has crippled the financial viability of state-legal cannabis businesses across the country.

The proposed rule, submitted to the Federal Register by the Drug Enforcement Administration (DEA), seeks to move cannabis from Schedule I to Schedule III of the Controlled Substances Act. If finalized, this change would exempt cannabis companies from the punitive Internal Revenue Code Section 280E, potentially unlocking billions of dollars in tax savings and fundamentally reshaping the industry's economics.

For years, state-licensed cannabis dispensaries, growers, and processors have operated under a severe federal tax burden. Section 280E, enacted in 1982 to target illegal drug traffickers, prohibits any business dealing in Schedule I or II controlled substances from deducting standard business expenses. This includes costs such as rent, payroll, utilities, and marketing. Consequently, cannabis companies have been forced to pay federal income tax on their gross profits rather than their net income, leading to effective tax rates that often exceed 70%.

This tax treatment has had a profound impact on small and mid-sized businesses in the sector. It has starved them of capital needed for growth, made it difficult to attract and retain talent, and suppressed their ability to compete with the unregulated illicit market, which pays no such taxes. The inability to deduct ordinary expenses has made many legally operating businesses appear unprofitable on paper, even when generating significant revenue, hindering their access to traditional loans and investment.

The recommendation to reschedule cannabis originated from the Department of Health and Human Services (HHS) in August 2023, following a comprehensive review of the plant's medical uses and potential for abuse. The HHS concluded that marijuana has a currently accepted medical use in the United States and a lower potential for abuse than other substances in Schedule I, such as heroin and LSD. The Justice Department’s formal proposal signals the final stages of the administrative review process.

The financial implications of this shift cannot be overstated. By moving to Schedule III, cannabis would be treated similarly to substances like ketamine, anabolic steroids, and Tylenol with codeine. Most importantly, Section 280E would no longer apply. A cannabis dispensary, for example, could finally deduct the salaries of its budtenders and the cost of its storefront lease from its taxable income. This would align its federal tax obligations with those of any other legal business, dramatically increasing post-tax profits and freeing up cash flow for reinvestment, expansion, and price reductions.

Industry analysts project that the elimination of 280E could save the legal cannabis industry more than $1 billion annually in federal taxes. For a mid-sized cannabis retailer, this could mean the difference between insolvency and sustainable growth. The newfound ability to generate and retain capital is expected to spur job creation, increase investment in safety and quality control, and bolster the financial health of the entire legal cannabis ecosystem.

The potential repeal of Section 280E for cannabis businesses represents the single most significant financial development for the industry in a generation. In our experience, many operators have been so focused on surviving under punitive tax rates that they have not fully modeled the operational impact of this change. It is not just about lower taxes; it is about fundamentally rethinking capital allocation, pricing strategies, and expansion plans. Businesses will need to immediately reassess their accounting practices to properly track and claim deductions that were previously disallowed. This requires proactive and sophisticated tax preparation and compliance to ensure they capture the full benefit without running afoul of new interpretations. We are advising clients to begin scenario planning now, so they are ready to act the moment a final rule is in place. For expert guidance on navigating this transition, business owners can contact C&S Finance Group LLC at csfinancegroup.com.

The path forward is not yet complete. The proposed rule has now entered a 60-day public comment period, after which the DEA will formulate and publish a final rule. While the change is widely anticipated, the process could still face legal challenges or administrative delays. Industry stakeholders and business owners will be closely watching the proceedings, as the final implementation will mark a pivotal turning point for the financial future of legal cannabis in the United States.